Consolidated Statements of Equity - USD ($)	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2015			10,000	5,673,302
Beginning Balance at Dec. 31, 2015	$ 23,283,824	$ 23,713,533	$ 100	$ 5,673	$ 396,547,401	$ 486	$ (372,132,490)	$ (707,637)	$ (429,709)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(33,309,533)	(32,656,319)					(32,656,319)		(653,214)
Unrealized loss on marketable securities	(486)	(486)				(486)
Share-based compensation (in shares)				114,344
Share-based compensation	(2,532,281)	(2,532,281)		$ (114)	(2,532,167)
Net proceeds from issuance of common stock (in shares)				2,418,144
Net proceeds from issuance of common stock	11,560,394	11,560,394		$ 2,419	11,557,975
Change in ownership in subsidiary	0	(265,494)			(265,494)				265,494
Ending Balance (in shares) at Dec. 31, 2016			10,000	8,205,790
Ending Balance at Dec. 31, 2016	4,066,480	4,883,909	$ 100	$ 8,206	410,372,049	0	(404,788,809)	(707,637)	(817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	22,228,087	22,978,700					22,978,700		(750,613)
Unrealized loss on marketable securities	(27,978)	(27,978)				(27,978)
Share-based compensation (in shares)				54,545
Share-based compensation	(2,494,471)	(2,494,471)		$ (55)	(2,494,416)
Net proceeds from issuance of common stock (in shares)				1,219,741
Net proceeds from issuance of common stock	5,701,686	5,701,686		$ 1,219	5,700,467
Proceeds from option exercises (in shares)				3,835
Proceeds from option exercises	13,576	13,576		$ 4	13,572
Elimination of equity associated with PCT sale	(3,686,536)	0			0				(3,686,536)
Conversion of redeemable securities	19,400,000	14,733,908			14,733,908				4,666,092
Change in ownership in subsidiary	0	(270,203)			(270,203)				270,203
Ending Balance (in shares) at Dec. 31, 2017			10,000	9,483,911
Ending Balance at Dec. 31, 2017	$ 50,189,786	$ 50,508,069	$ 100	$ 9,484	$ 433,044,209	$ (27,978)	$ (381,810,109)	$ (707,637)	$ (318,283)